An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of the investigational immunotherapy drug atezolizumab (also called MPDL3280A) in patients with solid tumors that continue to grow or came back despite prior therapy or for which no effective therapy exists. Atezolizumab is designed to improve the immune system's ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder cancer; its use in this study is considered investigational. It is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that continues to grow or came back despite prior therapy or for which no effective therapy exists. Examples include advanced cancers of the cervix, nasopharynx, colon/rectum, thyroid (anaplastic), bile duct, and stomach; cancers with BRCA1/2 mutations (including ovarian); soft tissue sarcoma; and mesothelioma.
- At least 3 weeks must pass between the completion of prior cancer treatment and entry into the study, and patients must recover from any serious side effects.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact the Immunotherapeutics Clinic at 646-888-3359.